medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2010, Number 1

<< Back Next >>

Evid Med Invest Salud 2010; 3 (1)

Sleep disorders in parkinson disease

Castillo-Hernández CD, García-Ramos GS

Language: Spanish
References: 62
Page: 8-25
PDF size: 264.80 Kb.


ABSTRACT

As the world’s population gets old, the neurodegenerative disorders will only grow in importance. The sleep disorders present in Parkinson’s disease are the main source of distress and worsening in the quality of life of these patients. This article will briefly review the normal sleep characteristics, before delving into the main manifestations of sleep disorders, the effects of PD’s treatment and of some comorbid disorders on sleep.


REFERENCES

  1. Diccionario de la lengua espańola de la Real Academia Espańola, vigésima segunda edición.

  2. Chen DK, Cordato DJ, O’Rourke F. Management for motor and non-motor complications in late Parkinson’s disease. Geriatrics 2008;63:22-27.

  3. Karlsen KH, Larsen JP, Tandberg E, Maeland JG. Influence of clinical and demographic variables on quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;66:431- 435.

  4. Chrischilles EA, Rubinstein LM, Voelker MD, et al. Linking clinical variables to health-related quality of life in Parkinson’s disease. Parkinsonism Relat Disord. 2002;8:199-209.

  5. Chaudhuri KR, Healy DG, Schapira AHV. Non motor symp toms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006;5:235–245.

  6. Hagell P, Nordling S, Reimer J et al (2002) Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov Disord 17:1213–1220

  7. Chaudhuri KR, Martinez-Martin P, MacPhee G et al. International multicenter pilot study of the first comprehensive self-comp leted nonmotor symp toms questionnaire for Parkinson’s disease: The NMSQuest study. Mov Disord 2006;21:916–923.

  8. Adler CH. Nonmotor comp lications in Parkinson’s Disease. Movement Disorders 2005;20:S23-S29.

  9. Martínez-Martín P, Cubo-Delgado E, Aguilar-Barberŕ M, Bergareched A, Escalante S, Rojo A, et al. Estudio piloto sobre una medida específica para los trastornos del sueńo de la enfermedad de Parkinson:SCO PA-sueńo. Rev Neurol 2006;43:577-583.

  10. Antonini A, Colosimo C, Marconi R, Morgante L, Barone P. The PRIAMO study: background, methods and recrui tment. Neurol Sci 2008;29:61–65.

  11. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson’s disease. Parkinsonism Relat Disord 2002;8:193–197.

  12. Braak H, Dei Tredici K, Rub U, de Vos RA . Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobio Aging. 2003;24(2):197-211.

  13. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neuroi. 2000;247(supp l 2):II3-II10.

  14. Wolcove N, Elkholy O, Baltzan M, et al. Sleep and aging: 1. Sleep disorders commonly found in older people. CMAJ 2007;176(9):1299–304.

  15. Kumar S, Bhatia M, Behari M. Sleep disorders in Parkinson’s disease. Mov Disord 2002;17:775–81.

  16. Rajput V, Bromley SM. Chronic insomnia: a practical review. Am Fam Physician 1999;60:1431–8 [discussion: 1441–2].

  17. Corman B, Leger D. Sleep disorders in elderly. Rev Prat 2004;54(12):1281–5.

  18. Monane M. Insomnia in the elderly. J Clin Psychiatry 1992;53(Supp l):23–8.

  19. Foley DJ, Monjan AA, Brown SL, et al. Sleep complaints among elderly persons:an epidemiologic study of three communities. Sleep 1995;18:425–32.

  20. Schmutte T, Harris S, Levi n R, et al. The relation between cognitive functioning and self-reported sleep complaints in nondemented older adults: results from the Bronx aging study. Behav Sleep Med 2007;5(1):39–56.

  21. Ancoli-Israel S. Epidemiology of sleep disorders. Clin Geriatr Med 1989;5:347– 62.

  22. Thorpy MJ, Adler CH. Parkinson’s Disease and Sleep. Neurol Clin 23 (2005) 1187–1208.

  23. Garcia AD. The Effect of Chronic Disorders on Sleep in the Elderly. Clin Geriatr Med 2008;24:27–38.

  24. Dowling GA, Mastick J, Colling E, Carter JH, Singer CM, Aminoff MJ. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Medicine 2005;6:459–466.

  25. Olanow CW , Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson’s disease: treatment guidelines. Neurology 2001;56(Supp l. 5):S1–S88. 1024.

  26. Chan DKY Insomnia, in: Chan DKY , ed. CHAN’S PRACT ICAL GERIATR ICS. Brookvaie, NSW, Australia: BA Printing & Pubii shing Servi ces;2006:200-204.

  27. Juri C, Chaná P, Tapi a J, Kunstmann C, Parrao T. Quetiapine for Insomnia in Parkinson Disease: Results From an Open-Label Trial.Clin Neuropharmacol 2005;28:185-187. 28.- Sabate M, Rodriguez M, Mendez E, et al. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson’s disease. Arch Phys Med Rehabil 1996;77:29–34.

  28. Ferini-Strambi L, Franceschi M, Pinto P, et al. Respiration and heart rate variability during sleep in untreated Parkinson patients. Gerontology 1992;38:92–8.

  29. Homann CN, Wenzel K, Suppan K et al. Sleep attacks in patients taking dopami ne agonists: review. BMJ. 2002; 324:1483-7.

  30. Plowman BK, Boggie DT , Morreale AP, Schaefer MG, Delattre ML, Chan H. Sleep attacks in patients receiving dopami ne-receptor agonists. Am J Health- Syst Pharm. 2005; 62:537-40.

  31. Frucht S, Rogers JD, Greene PE et al. Falling asleep at the wheel: motor vehicle mi shaps in persons taking pramip exole and ropinirole. Neurology. 1999; 52:1908-10. 33.- Happe S, Berger K. The association of dopami ne agonists with daytime sleepi - ness, sleep problems and quality of life in patients with Parkinson’s disease. J Neurol. 2001; 248:1062-7.

  32. Homann CN, Wenzel K, Suppan K et al. Sleep attacks in patients taking dopami ne agonists: review. BMJ. 2002; 324:1483-7.

  33. Johns MW. A new method for measuring daytim esleepiness: the Epworth Sleepi - ness Scale. Sleep 1991;14:540 –545.

  34. Kaynak D, Kiziltan G, Kaynak H, Benbir G, Uysal O. Sleep and sleepi ness in patients wi th Parkinson’s disease before and after dopaminergic treatment. Eur J of Neurol 2005, 12: 199–207.

  35. Möller JC, Oertel WH, Köster J, Pezzoli G, Provi nciali L. Long-Term Efficacy and Safety of Pramip exole in Advanced Parkinson’s Disease: Results From a European Multicenter Trial. Movement Disorders 2005;20:602-610.

  36. Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, Theitler J, et al. Excessiv e Daytim e Sleepiness in Patients With Parkinson’s Disease: A Polysomnography Study. Mov Disord 2006;21:1432-1438.

  37. Tandberg E, Larsen JP, Karlsen K. Excessiv e daytim esleepiness and sleep benefit in Parkinson’s disease: a community-based study. Mov Disord 1999;14:922–927.

  38. Roth T, Rye DB, Borchert LD, et al. Assessment of sleepiness and unintended sleep in Parkinson’s disease patients taking dopami neagonists. Sleep Med 2003;4:275–280.

  39. Chaudhuri KR, Martinez-Martin P. Clinical assessment of nocturnal disability in Parkinson’s disease: the Parkinson’s disease sleep scale. Neurology 2004;63:S17-S20.

  40. Chaudhuri KR, Pal S, DiMarco A, Whately- Smith C, Bridgman K, Mathew R, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2002; 73:629-35.

  41. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Mov Disord 2003;18:287– 293.

  42. Ondo WG, Fayle R, Atassi F, Jankovi c J. Modafinil for daytim e somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636– 1639.

  43. Ondo WG, Perkins T, Swi ck T, Hull KL, Jimenez JE, Garris TS et al. Sodium Oxybate for Excessive Daytime Sleepiness in Parkinson Disease: an Open-Label Polysomnographic Study. Arch Neurol 2008;65):1337-1340.

  44. Comella CL. Sleep disturbances in Parkinson’s disease. Curr Neurol Neurosci Rep 2003;3:173–180.

  45. Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: A controlled study using actigraphy. Neurology 2005;64:1450 –1451.

  46. Adler CH. Nonmotor complications in Parkinson’s Disease. Movement Disorders 2005;20:S23-S29.

  47. Comella CL. Sleep and Parkinson’s disease. In: Adler CH, Ahlskog JE, editors. Parkinson’s disease and movement disorders: diagnosis and treatment guidelines for the practicing physician. Totowa: Humana Press; 2000. p 151–160.

  48. Iranzo A et al. The clinical and pathophysiological relevance of REM sleep behavior disorder in neurodegenerative diseases. Sleep Medicine Revi ews (2009). Doi:10.1016/j.smrv.2008.11.03. In press.

  49. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless leg syndrome (RLS) in a primary care population: the REST (RLS epi demi ology, symp toms, and treatment) prim ary care study. Sleep Med. 2004;5:237-246.

  50. Ondo WG, Vuong KD, Khan H, et al. Daytime sleepiness and other sleep disorders in Parkinson’s disease. Neurology 2001;57:1392–6.

  51. Arnulf I, Konofal E, Merino-Andreu M, et al. Parkinson’s disease and sleepi - ness: an integral part of PD. Neurology 2002;58:1019–24.

  52. Happe S, Pirker W, Klosch G, et al. Periodic leg movements in patients with Parkinson’s disease are associated with reduced striatal dopamine transporter binding. J Neurol 2003;250:83–6.

  53. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study with periodic limb movement disorder and restless legs syndrome. Neurology. 2000;54:502- 504.

  54. Allen RP, Picchietti D, Hening WA , et al; for the Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health and the International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology, A report from the restless leg syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101-119.

  55. Allen RP, Walters AS, Montplaisir J, et al. Restless leg syndrome prevelance and imp act: REST general population study. Arch Intern Med. 2005;165:1286- 1292.

  56. Thorpy MJ. New pardigms in the treatment of restless legs syndrome. Neurology. 2005;64:S28-S33.

  57. Catala MD, Canete-Nicolas C, Iradi A, et al. Melatonn levels in Parkinson’s disease: drug therapy versus electrical stimulati on of the internal globus pallidus. Exp Gerontol 1997;32(4/5):553–8.

  58. Mendes CA , Carvalhedo PF, Lopes LA, Magalhăes MC, Seabra ML, Sales VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease: a randomized, double blind, placebo-controlled study. J Neurol 2007;254:459–464.

  59. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerativ e diseases. Neurotox Res 2005;7:293-318.

  60. Zisapel N. Melatonin-dopami ne interactions: from basic neurochemi stry to a clinical setting. Cell Mol Neurobiol 2001;21:605-616.

  61. Paus S, Schmi tz-Hübsch T, Wüllner U, Vogel A, Klockgether T, Abele M. Bright light therapy in Parkinson’s diseas: a pi - lot study. Mov Disord 2007;22:1495- 1498.

  62. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387–92.




2020     |     www.medigraphic.com